Source: Annual Congress 2001 - Pulmonary hypertension (miscellanea)
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. E. Iartseva, V. E. Perley, V. A. Goncharova (Saint-Petersburg, Russia). A possible role of plasma serotonin (5-HT) and histamin level in pulmonary hypertension (PH) in patients with interstitial lung diseases (ILD). Eur Respir J 2001; 16: Suppl. 31, 2815

Member's Comments

No comment yet.

Related content which might interest you: The role of secondary pulmonary hypertension (SPH) in the limited exercise tolerance of patients with interstitial lung disease (ILD) Source: Eur Respir J 2005; 26: Suppl. 49, 560s Year: 2005 Bosentan treatment in pulmonary arterial hypertension (PAH) associated with interstitial lung diseases (ILDs) Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006 Longterm treatment effects of pulmonary hypertantion (PH) in idiopathic pulmonary fibrosis (IPF) patients by endothelin receptor blockade (Bosentan) Source: Eur Respir J 2007; 30: Suppl. 51, 120s Year: 2007 Over expression of endothelin-1 (ET-1) in lung fibroblasts (LFb) from patients with pulmonary arterial hypertension (PAH), evidence for loss of inhibitory control Source: International Congress 2016 – New findings in mucosal immunology Year: 2016 Impact of borderline (BL) pulmonary hypertension (PH) in chronic lung diseases (CLD). Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Endothelin receptor antagonist (ETRA) bosentan (B) in patients with severe pulmonary hypertension (PH) associated with pulmonary disease Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 The composite physiological index strongly predicts mortality in interstitial lung disease (ILD) associated pulmonary hypertension (PH-ILD) Source: International Congress 2017 – Imaging and lung disease PH Year: 2017 Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Pulmonary hypertension (PH) and features of pulmonary circulation in patient with lung sarcoidosis (LS) Source: Eur Respir J 2006; 28: Suppl. 50, 354s Year: 2006 Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 Inflammatory biomarkers in patients with COPD and pulmonary hypertension (PH). Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019 Pulmonary rehabilitation (PR) outcomes in chronic obstructive pulmonary disease (COPD) compared with interstitial lung disease (ILD) Source: Annual Congress 2011 - Pulmonary rehabilitation: looking at alternative approaches and alternative populations beyond COPD Year: 2011 Comparison of pulmonary hypertension (PH) associated to chronic lung disease to other PH groups Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 Effects of an acute exacerbation requiring hospitalisation (AE) on lung function, muscle force and serum IGF-I levels in male patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 564s Year: 2002 Alveolar lymphocytes (AL) apoptosis in interstitial lung diseases (ILD). Increased AL apoptosis rate in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis Year: 2009 Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2017 – PAH and CTEPH Year: 2017 Increased lung apoptosis and expression of ceramide in subjects with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2009 - COPD: basic science and clinical studies Year: 2009 Increased expression of phosphodiesterase 4 (PDE4) A, B and D in alveolar macrophages from chronic obstructive pulmonary disease (COPD) patients Source: Annual Congress 2011 - Macrophages and neutrophils in chronic lung disease Year: 2011 Plasma level of total hydroperoxide (TH) as a marker of oxidative stress seems to be a useful index of disease severity in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2005; 26: Suppl. 49, 335s Year: 2005